Record-Breaking Price Movement
On 31 Dec 2025, Laurus Labs Ltd’s stock price closed just 0.42% shy of its 52-week high of ₹1,097.5, marking a significant milestone in its trading history. The stock recorded a daily gain of 0.93%, outperforming the Sensex’s 0.42% rise on the same day. Over the past week, the stock appreciated by 1.48%, while the Sensex declined by 0.44%. This positive momentum extended over longer periods, with a 7.00% gain in the last month and an impressive 26.25% increase over three months, compared to the Sensex’s respective declines and modest gains.
Notably, Laurus Labs has been on a consecutive two-day gain streak, delivering a cumulative return of 1.01% during this period. The stock is trading above all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling sustained upward momentum and investor confidence in its valuation.
Strong Long-Term Performance Against Benchmarks
Over the past year, Laurus Labs Ltd has generated a remarkable return of 82.78%, significantly outpacing the Sensex’s 8.82% gain. This outperformance extends over multiple time horizons, with the stock delivering 193.47% returns over three years and 211.75% over five years, compared to the Sensex’s 39.76% and 78.08% respectively. Such market-beating performance highlights the company’s ability to sustain growth and create shareholder value over the long term.
Strong fundamentals, solid momentum, fair price – This Large Cap from the NBFC sector checks every box for our Top 1%. This should definitely be on your radar!
- - Complete fundamentals package
- - Technical momentum confirmed
- - Reasonable valuation entry
Financial Strength and Profitability Metrics
Laurus Labs Ltd’s financial performance has been characterised by robust profitability and efficient capital utilisation. The company reported a net profit growth of 993.4% in its September 2025 quarter, reflecting very positive quarterly results. This marks the fourth consecutive quarter of positive earnings, underscoring consistent operational strength.
Profit before tax excluding other income (PBT LESS OI) for the quarter stood at ₹242.77 crores, representing a staggering growth of 1,233.17%. Similarly, the profit after tax (PAT) reached ₹194.97 crores, up by 882.7% compared to previous periods. The operating profit to interest ratio for the quarter was an impressive 10.08 times, indicating strong coverage of interest expenses by operating earnings.
The company’s return on capital employed (ROCE) remains high at 16.75%, reflecting efficient use of capital to generate earnings. This metric is a key indicator of management effectiveness and operational excellence within the Pharmaceuticals & Biotechnology sector.
Institutional Confidence and Market Position
Institutional investors hold a significant 37.63% stake in Laurus Labs Ltd, signalling strong confidence from entities with extensive analytical resources. Such holdings often correlate with thorough fundamental analysis and long-term commitment, providing stability to the stock’s price movements.
Despite the stock’s recent gains, it trades at a discount relative to its peers’ average historical valuations, suggesting a degree of valuation prudence in the market. The company’s enterprise value to capital employed ratio stands at 8.8, which, combined with a ROCE of 14.9, indicates a valuation that is on the higher side but justified by strong profitability metrics.
Growth Trends and Valuation Considerations
While Laurus Labs Ltd has demonstrated exceptional profit growth, its operating profit has expanded at a more modest annual rate of 5.37% over the past five years. This suggests a steady but measured expansion in core operational earnings.
Over the last year, the company’s profits have surged by 421.7%, outstripping the stock’s 82.78% return and resulting in a price-to-earnings-growth (PEG) ratio of 0.2. This low PEG ratio indicates that the stock’s price growth has not fully reflected the rapid earnings acceleration, a factor that may be of interest to market participants analysing valuation dynamics.
Thinking about Laurus Labs Ltd? Our real-time Verdict report breaks down everything – from financial health and peer comparison to technical signals and fair valuation for this mid-cap stock!
- - Real-time Verdict available
- - Financial health breakdown
- - Fair valuation calculated
Mojo Score and Market Capitalisation
Laurus Labs Ltd holds a Mojo Score of 77.0, with a current Mojo Grade of Buy, following a downgrade from Strong Buy on 9 June 2025. The company’s market capitalisation grade is 2, reflecting its standing within the Pharmaceuticals & Biotechnology sector and its relative size in the market.
The stock’s recent performance has slightly underperformed its sector by 0.25% on the day of the all-time high, yet it continues to demonstrate strong relative strength against broader market indices and sector peers.
Summary of the Stock’s Journey
From a long-term perspective, Laurus Labs Ltd has delivered exceptional returns, with a 3-year gain of 193.47% and a 5-year gain of 211.75%, far exceeding the Sensex’s respective returns of 39.76% and 78.08%. The stock’s ability to maintain upward momentum across multiple time frames, combined with strong financial results and institutional backing, has culminated in this record-setting price achievement.
Trading above all major moving averages and maintaining a consistent upward trajectory over recent days, Laurus Labs Ltd’s stock price reflects the company’s solid fundamentals and operational efficiency. The milestone of reaching an all-time high is a testament to its sustained growth and market resilience within the Pharmaceuticals & Biotechnology sector.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Today
